文献速递肝病消化道肿瘤与早癌

肝细胞癌中协同激活的间变性淋巴瘤激酶、成纤维细胞生长因子受体2与肝配蛋白A型受体5激酶的鉴定及治疗干预

Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2018-03-24

研究旨在鉴定协同驱动肝细胞癌恶性生长的激酶簇。发现间变性淋巴瘤激酶、成纤维细胞生长因子受体2和肝配蛋白A型受体5组成功能簇,通过下游蛋白激酶B依赖、细胞外信号调节激酶依赖和p38依赖信号通路维持肝癌细胞存活,其协同激活与约13%肝细胞癌患者总生存预后不良相关,且受热休克蛋白90调控;联合激酶抑制或靶向热休克蛋白90在体外和体内均产生显著治疗反应。

要点

  • 间变性淋巴瘤激酶、成纤维细胞生长因子受体2和肝配蛋白A型受体5组成功能簇维持肝癌细胞存活。
  • 三者协同激活与约13%肝细胞癌患者总生存预后不良相关。
  • 联合激酶抑制或靶向热休克蛋白90在体外和体内均产生显著治疗反应。

核心结论

  • 研究建立了一个范式,突出间变性淋巴瘤激酶、成纤维细胞生长因子受体2和肝配蛋白A型受体5激酶在主导肝细胞癌细胞生长优势中的协同作用,可能为部分肝细胞癌患者的诊断和后续干预提供概念性的「联合治疗靶点」。

研究设计与样本

  • 本研究旨在鉴定可能协同驱动肝细胞癌恶性生长的激酶簇,并在体外和体内进行验证。

主要发现

  • 间变性淋巴瘤激酶、成纤维细胞生长因子受体2和肝配蛋白A型受体5是组装成功能簇以维持肝细胞癌细胞活力的关键激酶。
  • 该功能簇通过下游蛋白激酶B依赖、细胞外信号调节激酶依赖和p38依赖信号通路发挥作用。
  • 三者协同激活与约13%肝细胞癌患者的总生存预后不良相关。
  • 三者的活性受热休克蛋白90紧密调控。
  • 联合激酶抑制或靶向热休克蛋白90在体外和体内均导致显著治疗反应。

关键数值与推荐

  • 间变性淋巴瘤激酶、成纤维细胞生长因子受体2和肝配蛋白A型受体5协同激活与约13%肝细胞癌患者的总生存预后不良相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Though kinase inhibitors have been heavily investigated in the clinic to combat advanced hepatocellular carcinoma (HCC), clinical outcomes have been disappointing overall, which may be due to the absence of kinase-addicted subsets in HCC patients. Recently, strategies that simultaneously inhibit multiple kinases are increasingly appreciated in HCC treatment, yet they are challenged by the dynamic nature of the kinase networks. This study aims to identify clustered kinases that may cooperate to drive the malignant growth of HCC. We show that anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type-A receptor 5 are the essential kinases that assemble into a functional cluster to sustain the viability of HCC cells through downstream protein kinase B-dependent, extracellular signal-regulated kinase-dependent, and p38-dependent signaling pathways. Their coactivation is associated with poor prognosis for overall survival in about 13% of HCC patients. Moreover, their activities are tightly regulated by heat shock protein 90 (Hsp90). Thereby Combined kinase inhibition or targeting of heat shock protein 90 led to significant therapeutic responses both in vitro and in vivo. Conclusion: Our findings established a paradigm that highlights the cooperation of anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type-A receptor 5 kinases in governing the growth advantage of HCC cells, which might offer a conceptual "combined therapeutic target" for diagnosis and subsequent intervention in a subgroup of HCC patients.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhang M, Ping F, et al. Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology. 2018. PMID: 29356025. doi:10.1002/hep.29792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。